Silverarc Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Silverarc Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.22M	Buy	419,949 +25,299	+6%	+$235K	0.33%	50
2025 Q4	$4.46M	Buy	+394,650	New	+$4.02M	0.62%	42
2024 Q3	–	Sell	-398,436	Closed	-$2.47M	–	75
2024 Q2	$2.47M	Hold	398,436	–	–	0.58%	50
2024 Q1	$3.76M	Buy	+398,436	New	+$3.56M	1.04%	30
2021 Q4	–	Sell	-185,691	Closed	-$5.24M	–	80
2021 Q3	$5.24M	Buy	+185,691	New	+$3.52M	2.96%	9
2021 Q2	–	Sell	-121,302	Closed	-$1.43M	–	106
2021 Q1	$1.43M	Buy	121,302 +105,093	+648%	+$1.3M	0.78%	47
2020 Q4	$190K	Buy	+16,209	New	+$183K	0.11%	80

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Silverarc Capital Management's FULC Position: Q1 2026 in Review

Silverarc Capital Management increased its Fulcrum Therapeutics (FULC) stake by 6.4% in Q1 2026, buying an estimated $235K and bringing the position to 419,949 shares worth $3.22M. The position accounts for 0.33% of the portfolio, ranked #50.

Silverarc Capital Management first reported a position in FULC in Q4 2020 and has held it in 7 quarters since. The position peaked at $5.24M in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Silverarc Capital Management held 419,949 shares of Fulcrum Therapeutics worth $3.22M as of Q1 2026.
Silverarc Capital Management bought 25,299 Fulcrum Therapeutics shares in Q1 2026, an estimated $235K.
Fulcrum Therapeutics made up 0.33% of Silverarc Capital Management's portfolio in Q1 2026, its #50 holding.
Silverarc Capital Management first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 7 quarters since.
Silverarc Capital Management's Fulcrum Therapeutics position peaked at $5.24M in Q3 2021.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.